Quick Answer
DiaMedica Therapeutics Inc. reported R&D Expense of $24.61 million for fiscal year 2025.
DiaMedica Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $24.61M | +29.2% |
| 2024 | $19.06M | +45.4% |
| 2023 | $13.11M | +67.2% |
| 2022 | $7.84M | -10.6% |
| 2021 | $8.77M | +6.8% |
| 2020 | $8.21M | +3.9% |
| 2019 | $7.90M | +74.7% |
| 2018 | $4.52M | +41.0% |
| 2017 | $3.21M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.44M | +29.2% | +10.6% |
| June 30, 2025 | $5.82M | +48.2% | +2.9% |
| March 31, 2025 | $5.66M | +53.9% | +13.5% |
| September 30, 2024 | $4.98M | +52.3% | +26.9% |
| June 30, 2024 | $3.93M | +54.5% | +6.9% |
| March 31, 2024 | $3.68M | +1.6% | +12.3% |
| September 30, 2023 | $3.27M | +99.5% | +28.7% |
| June 30, 2023 | $2.54M | +30.1% | -29.7% |
- DiaMedica Therapeutics Inc. showed an increase of +29.2% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, DiaMedica Therapeutics Inc.’s r&d expense has grown by 667.7% (from $3.21 million to $24.61 million).
- The most recent figure is from DiaMedica Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: